Patient abusing alcohol or drugs? Help starts with a single question

,

Applied Evidence

Patient abusing alcohol or drugs? Help starts with a single question

J Fam Pract. 2013 February;62(2):63-69

PDF Download

References

Friedman PD. Alcohol use in adults. N Engl J Med. 2013;368:365-373.
Williams RH, Vinson DC. Validation of a single question screen for problem drinking. J Fam Pract. 2001;50:307-312.
Smith PC, Schmidt SM, Allensworth-Davies D, et al. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;74:783-788.
Dawson DA, Pulay AJ, Grant BF. A comparison of two single-item screeners for hazardous drinking and alcohol use disorder. Alcohol Clin Exp Res. 2010;34:364-374.
Bush K, Kivlahan DR, Mcdonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789-1795.
Dawson DA, Grant BF, Stinson FS, et al. Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res. 2005;29:844-854.
Smith PC, Schmidt SM, Allensworth-Davies D, et al. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170:1155-1160.
American Psychiatric Asociation. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. (DSM-IV-TR). Arlington, Va: American Psychiatric Association; 2000.
Saha TD, Stinson FS, Grant BF. The role of alcohol consumption in future classifications of alcohol use disorders. Drug Alcohol Depend. 2007;89:82-92.
Vinson DC, Kruse RL, Seale JP. Simplifying alcohol assessment:two questions to identify alcohol use disorders. Alcohol Clin Exp Res. 2007;31:1392-139.
Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. J Clin Epidemiol. 2004;57:30-39.
Johnson JA, Lee A, Vinson DC, et al. Use of AUDIT-based measures to identify unhealthy alcohol use and alcohol dependence in primary care: a validation study. Alcohol Clin Exp Res. 2012;July 26 [Epub ahead of print].
Center for Adolescent Substance Abuse Research. The CRAFFT Screening Tool. Boston MA:2009 [updated 2012). Available at: http://www.ceasar-boston.org/clinicians/crafft.php. Accessed January 15, 2013.
Knight JR, Sherritt L, Harris SK, et al. Validity of brief alcohol screening tests among adolescents: a comparison of the AUDIT, POSIT, CAGE, and CRAFFT. Alcohol Clin Exp Res. 2003;27:67-734.
Wallace P, Cutler S, Haines A. Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. BMJ. 1988;297:663-668.
Fleming MF, Barry KL, Manwell LB, et al. Brief physician advice for problem alcohol drinkers: a randomized controlled trial in community-based primary care practices. JAMA. 1997;277:1039-1044.
Bertholet N, Daeppen JB, Wietlisbach V, et al. Brief alcohol intervention in primary care reduces alcohol consumption: Systematic review and meta-analysis. Arch Intern Med. 2005;165:986-995.
Kaner EFS, Dickinson HO, Beyer F, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007(2);CD004148.-
Fleming MF, Mundt MP, French MT, et al. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res. 2002;26:36-43.
Cuijpers P, Riper H, Lemmers L. The effects on mortality of brief interventions for problem drinking: a meta-analysis. Addiction. 2004;99:839-845.
U.S.Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140:554-556.
Saitz R, Alford DP, Bernstein J, et al. Screening and brief intervention ffor unhealthy drug use in primary care settings: randomized clinical trials are needed. J Addict Med. 2010;4:131-136.
Field CA, Baird J, Saitz R, et al. The mixed evidence for brief intervention in emergency departments, trauma care centers, and inpatient hospital settings: what should we do? Alcohol Clin Exp Res. 2010;34:2004-2010.
DiClemente CC, Prochaska JO. Toward a comprehensive transtheoretical model of change: stages of change and addictive behaviors. In: Miller WR, Heather N, eds. Treating Addictive Behaviors. New York, NY:Plenum Press;1998:3–24.
Mason P, Butler CC. Health Behavior Change: A Guide for Practitioners. 2nd ed. London UK:Elsevier; 2010.
Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York NY: Guilford Press;2002.
Hettema J, Steele J, Miller WR. Motivational interviewing. Ann Rev Clin Psych. 2005;1:91-111.
Rollnick S, Butler CC, Kinnersley P, et al. Motivational interviewing. BMJ. 2010;340:c1900.-
Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.-
Swift R, Oslin DW, Alexander M, et al. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs. 2011;72:1012-1018.
Pettinati HM, Silverman BL, Battisti JJ, et al. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011;35:1804-1811.
Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010(9);CD004332.-
Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2012;October 17 [Epub ahead of print].
Azrin NH. Improvements in the community-reinforcement approach to alcoholism. Behav Res Ther. 1976;14:339-348.
Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatr. 1982;13:105-112.
Keane TM, Foy DW, Nunn B, et al. Spouse contracting to increase antabuse compliance in alcoholic veterans. J Clin Psychol. 1984;40:340-344.
Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, et al. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Espanolas de Psiquiatria. 2010;38:8-12.
Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75:34-56.
Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284:963-971.
Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatr. 2011;168:265-275.
Pettatini HM, Oslin D, Lampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatr. 2010;167:668-675.
Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatr. 2011;168:709-717.
Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582-1588.
Elkashef A, Kahn R, Yu E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107:1297-1306.
Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatr. 2011;68:1168-1175.
Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37:1689-1698.
Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169:805-812.
Farrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. BMJ. 2012;344.-
Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39:340-352.
Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515-532.
Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283:1303-1310.
Clausen T, Anchersen K, Waal H. Mortality prior to during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94:151-157.
Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs. 2011;30:1425-1433.
Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40. Rockville Md: Substance Abuse and Mental Health Services Administration; 2004.
Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
Fiellin DA. Buprenorphine: effective treatment of opioid addiction starts in the office. Am Fam Physician. 2006;73:1513.-
Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintainance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333.-
Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-1513.

References

Friedman PD. Alcohol use in adults. N Engl J Med. 2013;368:365-373.
Williams RH, Vinson DC. Validation of a single question screen for problem drinking. J Fam Pract. 2001;50:307-312.
Smith PC, Schmidt SM, Allensworth-Davies D, et al. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;74:783-788.
Dawson DA, Pulay AJ, Grant BF. A comparison of two single-item screeners for hazardous drinking and alcohol use disorder. Alcohol Clin Exp Res. 2010;34:364-374.
Bush K, Kivlahan DR, Mcdonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789-1795.
Dawson DA, Grant BF, Stinson FS, et al. Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res. 2005;29:844-854.
Smith PC, Schmidt SM, Allensworth-Davies D, et al. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170:1155-1160.
American Psychiatric Asociation. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. (DSM-IV-TR). Arlington, Va: American Psychiatric Association; 2000.
Saha TD, Stinson FS, Grant BF. The role of alcohol consumption in future classifications of alcohol use disorders. Drug Alcohol Depend. 2007;89:82-92.
Vinson DC, Kruse RL, Seale JP. Simplifying alcohol assessment:two questions to identify alcohol use disorders. Alcohol Clin Exp Res. 2007;31:1392-139.
Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. J Clin Epidemiol. 2004;57:30-39.
Johnson JA, Lee A, Vinson DC, et al. Use of AUDIT-based measures to identify unhealthy alcohol use and alcohol dependence in primary care: a validation study. Alcohol Clin Exp Res. 2012;July 26 [Epub ahead of print].
Center for Adolescent Substance Abuse Research. The CRAFFT Screening Tool. Boston MA:2009 [updated 2012). Available at: http://www.ceasar-boston.org/clinicians/crafft.php. Accessed January 15, 2013.
Knight JR, Sherritt L, Harris SK, et al. Validity of brief alcohol screening tests among adolescents: a comparison of the AUDIT, POSIT, CAGE, and CRAFFT. Alcohol Clin Exp Res. 2003;27:67-734.
Wallace P, Cutler S, Haines A. Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. BMJ. 1988;297:663-668.
Fleming MF, Barry KL, Manwell LB, et al. Brief physician advice for problem alcohol drinkers: a randomized controlled trial in community-based primary care practices. JAMA. 1997;277:1039-1044.
Bertholet N, Daeppen JB, Wietlisbach V, et al. Brief alcohol intervention in primary care reduces alcohol consumption: Systematic review and meta-analysis. Arch Intern Med. 2005;165:986-995.
Kaner EFS, Dickinson HO, Beyer F, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007(2);CD004148.-
Fleming MF, Mundt MP, French MT, et al. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res. 2002;26:36-43.
Cuijpers P, Riper H, Lemmers L. The effects on mortality of brief interventions for problem drinking: a meta-analysis. Addiction. 2004;99:839-845.
U.S.Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140:554-556.
Saitz R, Alford DP, Bernstein J, et al. Screening and brief intervention ffor unhealthy drug use in primary care settings: randomized clinical trials are needed. J Addict Med. 2010;4:131-136.
Field CA, Baird J, Saitz R, et al. The mixed evidence for brief intervention in emergency departments, trauma care centers, and inpatient hospital settings: what should we do? Alcohol Clin Exp Res. 2010;34:2004-2010.
DiClemente CC, Prochaska JO. Toward a comprehensive transtheoretical model of change: stages of change and addictive behaviors. In: Miller WR, Heather N, eds. Treating Addictive Behaviors. New York, NY:Plenum Press;1998:3–24.
Mason P, Butler CC. Health Behavior Change: A Guide for Practitioners. 2nd ed. London UK:Elsevier; 2010.
Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York NY: Guilford Press;2002.
Hettema J, Steele J, Miller WR. Motivational interviewing. Ann Rev Clin Psych. 2005;1:91-111.
Rollnick S, Butler CC, Kinnersley P, et al. Motivational interviewing. BMJ. 2010;340:c1900.-
Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.-
Swift R, Oslin DW, Alexander M, et al. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs. 2011;72:1012-1018.
Pettinati HM, Silverman BL, Battisti JJ, et al. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011;35:1804-1811.
Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010(9);CD004332.-
Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2012;October 17 [Epub ahead of print].
Azrin NH. Improvements in the community-reinforcement approach to alcoholism. Behav Res Ther. 1976;14:339-348.
Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatr. 1982;13:105-112.
Keane TM, Foy DW, Nunn B, et al. Spouse contracting to increase antabuse compliance in alcoholic veterans. J Clin Psychol. 1984;40:340-344.
Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, et al. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Espanolas de Psiquiatria. 2010;38:8-12.
Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75:34-56.
Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284:963-971.
Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatr. 2011;168:265-275.
Pettatini HM, Oslin D, Lampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatr. 2010;167:668-675.
Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatr. 2011;168:709-717.
Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582-1588.
Elkashef A, Kahn R, Yu E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107:1297-1306.
Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatr. 2011;68:1168-1175.
Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37:1689-1698.
Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169:805-812.
Farrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. BMJ. 2012;344.-
Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39:340-352.
Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515-532.
Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283:1303-1310.
Clausen T, Anchersen K, Waal H. Mortality prior to during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94:151-157.
Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs. 2011;30:1425-1433.
Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40. Rockville Md: Substance Abuse and Mental Health Services Administration; 2004.
Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
Fiellin DA. Buprenorphine: effective treatment of opioid addiction starts in the office. Am Fam Physician. 2006;73:1513.-
Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintainance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333.-
Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-1513.

Patient abusing alcohol or drugs? Help starts with a single question

References

Pages

Recommended Reading